The Best Biotech Stock to Invest $1,000 in Right Now
Viking Therapeutics is developing medicines to fight obesity -- a hot area now. Its lead program appears to work better than blockbuster drugs made by others.
Why Viking Therapeutics Stock Price Moved Down 6% on Tuesday
VKTX's shares fell after rival Eli Lilly announced that it is launching cheaper versions of Zepbound to strengthen its presence in the obesity market.
Why Viking Therapeutics Stock Got Thrashed on Tuesday
A very competitive peer has launched a discount offering in a white-hot corner of the pharmaceutical market. Viking is still in development with its own drug in the category.
Brokers Suggest Investing in Viking Therapeutics (VKTX): Read This Before Placing a Bet
The recommendations of Wall Street analysts are often relied on by investors when deciding whether to buy, sell, or hold a stock. Media reports about these brokerage-firm-employed (or sell-side) analysts changing their ratings often affect a stock's price.
Viking Therapeutics Stock Could Rocket 76% Higher According to Wall Street. Is It a Buy Now?
Viking Therapeutics stock has already tripled in 2024, but Wall Street analysts think it has more room to run. Viking Therapeutics' lead candidate is an experimental weight management treatment that could end up competing with Zepbound from Eli Lilly.
Viking (VKTX) Rises 25% in a Month: Should You Buy or Wait?
Despite having no marketed drugs, Viking's (VKTX) stock continues to experience robust price movement, driven by the company's encouraging progress with its pipeline.
Massive Weight Loss Market: Viking (VKTX) is Best-in-Breed
Viking Therapeutics (VKTX) has developed a best-in-breed GLP-1 drug. The company is poised to gain a large portion of the massive weight loss drug market.
Could Viking Therapeutics Become the Next Novo Nordisk?
Viking Therapeutics has a high valuation for a company with no sales. Novo Nordisk is competing in the same market, and that market is growing rapidly.
Better Weight Loss Drug Stock: Viking Therapeutics vs. Zealand Pharma
Viking Therapeutics has a powerful weight loss candidate in late-stage trials. Zealand Pharma has a handful of programs and a powerful collaborator.
The Bull Case for Viking Therapeutics Just Got Even Stronger. Here's Why You Should Buy It.
The upstart biotech just reported its Q2 earnings -- and investors were pleased. All of its programs are proceeding according to plan, and it isn't spending much.
Attention, Growth Investors: This Biotech Stock Is Crushing Nvidia.
Artificial intelligence (AI) chip leader Nvidia has soared 126% so far this year -- but this biotech stock has advanced even more. This biotech player is targeting a market that could be worth $100 billion by the end of the decade.
Is Viking Therapeutics a Millionaire-Maker Stock?
Viking is developing drug candidates in an area of high interest and growth: weight loss. The company is launching a phase 3 clinical trial for its first weight loss candidate.
